Association of estimated glucose disposal rate with metabolic syndrome prevalence and mortality risks: a population-based study
Authors' conclusion
eGDR is strongly associated with MetS and predicts all-cause and CVD mortality in individuals with MetS. Compared to TyG and HOMA-IR, eGDR offers superior predictive value for all-cause mortality, highlighting its potential as a useful tool in clinical risk assessment.
Study context
- Population
- NHANES participants (2001–2018); mortality analysis in individuals with metabolic syndrome (MetS)
- Exposure
- Estimated glucose disposal rate (eGDR) (per SD increment) vs MetS prevalence and mortality; eGDR vs TyG and HOMA-IR for prediction
- Outcome
- Association of eGDR with MetS prevalence (cross-sectional) and with all-cause and CVD mortality (cohort)
Methodological detailspopulation-based, NHANES 2001-2018, weighted logistic regression, weighted Cox proportional hazard models, restricted cubic spline analysis
- Population-based
- NHANES 2001-2018
- Weighted logistic regression
- Weighted Cox proportional hazard models
- Restricted cubic spline analysis
Main finding
As reported in the abstract
eGDR and MetS prevalence; all-cause and CVD mortality in MetS
- Robust negative association between eGDR and MetS prevalence after full covariate adjustment
- p < 0.001
- In MetS, all-cause mortality risk decrement per SD increment in eGDR
- 11%
- In MetS, cardiovascular disease (CVD) mortality risk decrement per SD increment in eGDR
- 18%
Observational data: associations, not effects.
Further findings
eGDR and MetS prevalence across subgroups
- Core findings consistent across subgroups
- all p < 0.001
Shape of associations (restricted cubic spline (RCS))
- Non-linear association between eGDR and MetS prevalence; linear association between eGDR and mortality
Predictive power for all-cause mortality (C-statistic)
- eGDR significantly improved predictive power vs TyG index and HOMA-IR
- P = 0.007
Original publication
Association of estimated glucose disposal rate with metabolic syndrome prevalence and mortality risks: a population-based study. Cardiovasc Diabetol. Published 22 January 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →